PHR:NYSEPhreesia, Inc. Analysis

Phreesia, Inc. (PHR) trades at $10.76, comfortably above its 20‑day ($10.20) and 50‑day ($9.72) SMAs but still below the 200‑day SMA ($14.41), signaling short‑term strength within a longer‑term downtrend. The MACD line sits bullish at 0.38 versus its signal at 0.34 and the RSI is 58.9, suggesting modest momentum without overbought pressure. Forward earnings are projected to surge, driving the forward P/E to a compelling 6.7 versus a trailing P/E of 67, and a discounted cash‑flow model values the stock near $20, implying roughly 30% upside from today’s price. Revenue grew 13% YoY to $496 M with a solid 68% gross margin, yet profitability remains thin (operating margin 5.1%, net margin 1.9%) and debt ($92.6 M) exceeds cash ($74.7 M). Volatility is high at 52% over the past 30 days, but beta is only 0.38, indicating limited market‑wide swing risk; however, decreasing volume and a pending securities class‑action deadline (July 13, 2026) add a layer of litigation risk. Overall, the stock appears undervalued relative to its DCF fair value and analyst consensus (Buy), but investors should weigh the litigation exposure and near‑term price volatility before committing.